FDA grants breakthrough therapy status to Arrowhead’s plozasiran
The US FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, a RNA interference (RNAi) therapeutic.
The US FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, a RNA interference (RNAi) therapeutic.
What's Your Reaction?
